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Abstract objective The vital status of patients lost to follow-up often remains unknown in antiretroviral
therapy (ART) programmes in sub-Saharan Africa because medical records are no longer updated
once the patient disengages from care. Thus, we aimed to assess the outcomes of patients lost to
follow-up after ART initiation in north-eastern South Africa.
methods Using data from a rural area in north-eastern South Africa, we estimated the cumulative
incidence of patient outcomes (i) after treatment initiation using clinical records, and (ii) after loss to
follow-up (LTFU) using data from clients that have been individually linked to Agincourt Health and
Demographic Surveillance System (AHDSS) database. Aside from LTFU, we considered mortality, re-
engagement and migration out of the study site. Cox proportional hazards regression was used to
identify covariates of these patient outcomes.
results Between April 2014 and July 2017, 3700 patients initiated ART and contributed a total of
6818 person-years of follow-up time. Three years after ART initiation, clinical record-based estimates
of LTFU, mortality and documented transfers were 41.0% (95% CI: 38.5–43.4%), 1.9% (95% CI
1.0–3.2%) and 0.1% (95% CI 0.0–0.9%), respectively. Among those who were LTFU, the
cumulative incidence of re-engagement, out-migration and mortality at 3 years were 38.1% (95% CI
33.1–43.0%), 49.4% (95% CI 43.1–55.3%) and 4.7% (95% CI 3.5–6.2%), respectively. Pregnant or
breastfeeding women, foreigners and those who initiated ART most recently were at an increased risk
of LTFU.
conclusion LTFU among patients starting ART in north-eastern South Africa is relatively high and
has increased in recent years as more asymptomatic patients have initiated treatment. Even though
this tendency is of concern in light of the prevention of onwards transmission, we also found that re-
engagement in care is common and mortality among persons LTFU relatively low.
keywords HIV/AIDs, loss to follow-up, re-engagement, competing risk analysis, record linkage,
demographic surveillance system
Introduction
Sustained use of antiretroviral therapy (ART) among
HIV-infected patients reduces HIV viral load to unde-
tectable levels, slows the progression of HIV and reduces
the risk of onwards sexual transmission [1, 2]. However,
high rates of loss to follow-up (LTFU) have been reported
in many HIV care and treatment programmes in sub-
Saharan Africa [3–5]. Perception of good health, use of
alternative medicine, stigma, treatment fatigue, lack of
knowledge, transport fare and competing demands for
time are some of the factors that are known to contribute
to disengagement [6]. However, not all patients deemed
LTFU have stopped taking ART, as some patients switch
facilities [7, 8]. Thus it is important to better understand
the vital and treatment status of the LTFU patients both
for improving the delivery of HIV services and for esti-
mating the impact of ART on HIV-associated mortality.
Several strategies have been employed to obtain infor-
mation on the vital status of patients LTFU, including
patient tracing, the review of obituaries in newspapers
and record linkage with Civil Registration and Vital
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Statistics [9, 10]. The IeDEA Network used sample-based
tracing to locate LTFU by phone or home visits [8, 11,
12].
In this study, we used information from clinic records
that are individually linked with data from the Agincourt
Health and Demographic Surveillance System (AHDSS)
[13] in South Africa to ascertain both vital and migration
status of patients who are LTFU. The link with the
AHDSS also allowed us to identify patients who are
LTFU at one facility and subsequently registered at
another facility that serves the AHDSS population. We
use these data to estimate outcomes of patients after (i)
treatment initiation and (ii) LTFU.
Methods
Ethics statement
The study was approved by the University of the Witwa-
tersrand Human Research Ethics Committee and the
London School of Hygiene and Tropical Medicine
Research Ethics Committee. Data analysis was conducted
using anonymised data.
Study setting and population
The AHDSS study area covers 475 km2 in Bushbuck-
ridge, Mpumalanga province, north-eastern South
Africa. The AHDSS has been tracking demographic and
health events in people living in the HDSS boundary
since 1992. As of 2014, the population was approxi-
mately 115 000 individuals living in 17 000 households
spread across 31 villages [14]. Overall, 47.9% of the
population are men and 52.1% are women [15]. One
third of the population are former Mozambican refugees
who moved into the area during the civil war that
began in 1977 and ended in 1992. About 9 in 10 of the
former Mozambican refugees have now attained South
African citizenship [16].
A cross-sectional biomarker survey conducted in 2010–
2011 estimated that one in five adults in the AHDSS pop-
ulation were HIV-infected [17]. The likelihood of being
diagnosed with HIV was higher among South Africans
than foreigners [17]. HIV prevalence was higher among
women (23.9%) than men (10.6%), consistent with other
countries in sub-Sahara Africa (SSA) [18]. However, tem-
porary labour migration is quite high among young adult
men in the study site [19] and they may be under-repre-
sented in the AHDSS serosurvery [20].
ART provision began in 2004 in two secondary hospi-
tals, between 25 and 60 km away from the AHDSS study
area [13]. A community health centre, Bhubezi, was
opened in 2007 in the AHDSS study area and was the
first to provide HIV care and treatment locally. Cur-
rently, HIV care and treatment services have been decen-
tralised to 10 primary health care facilities in the AHDSS
study area (Figure 1). Initiation of ART among persons
newly diagnosed with HIV at these facilities is in line
with national antiretroviral therapy guidelines. Since
December 2014, these recommended ART initiation to
all pregnant or breastfeeding women and any patient
with a CD4 count <500/lL [21]. In September 2016, the
treatment eligibility criteria were further revised to
include all persons diagnosed with HIV [22].
To promote adherence two non-governmental organi-
sations conduct tracing of patients who disengage from
care (Right to Care and Home-Based Carers (HBCs)) in
the AHDSS catchment area. To that end, nurses at the
clinic prepare a list of patients LTFU and a Right to Care
linkage officer contacts these patients by phone. If a
patient cannot be traced by phone, the case is referred to
HBCs for physical tracing.
Data
The core data infrastructure for this study consists of
HIV patient records that are linked to the AHDSS using
Point-of-Contact Interactive Record Linkage (PIRL), a
procedure that has been described elsewhere [23]. In
brief, a field worker is stationed at the clinic reception
area to inform all new patients about the study objectives
and record linkage procedures. Patients who consent are
asked to declare a number of personal identifiers that are
used to search a local copy of the AHDSS database using
a probabilistic algorithm. Matches are confirmed in inter-
action with the patients, and the names of other house-
hold members are used as a key attribute to adjudicate
between possible matches. The PIRL software tool also
contains a provision to log follow-up visits [24].
Record linkage started in April 2014, at seven govern-
ment facilities and in 2016 this was extended to include
one additional health facility. In this study, we only
included patients who had been linked before or at the
time of ART initiation. From these eight health facilities,
we extracted the following information from the clinic
records; clinic visit dates, date of HIV diagnosis, date of
ART initiation, baseline CD4 counts, WHO clinical stag-
ing, reason for ART initiation, pregnancy status, vital sta-
tus (i.e. alive or dead from any cause), date of death and
availability of a duly completed facility transfer form.
The AHDSS database contains information obtained
from an annual household visits [13], including changes
in residency and the vital status of all household mem-
bers.
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Operational definitions
A patient who had commenced ART was considered
LTFU if they failed to return within 90 days of a sched-
uled appointment. Our analyses were conducted in two
stages. The first set of analyses only make use of clinic
attendance records, to prospectively follow patients from
the date of ART initiation to either LTFU, a documented
transfer, death or administrative censoring on the date of
data extraction from clinical records (i.e. 15 July 2017).
The second set of analyses make use of linked AHDSS
and clinic attendance records to evaluate the outcomes of
the patient who were deemed LTFU on the basis of their
clinical record. In this second set of analyses, time was
measured from the date of last clinic visit to the earliest
of the following events: re-engagement, out-migration
from the AHDSS, death or administrative censoring on
the date of last AHDSS household visit.
An individual was considered to have migrated if he or
she was reported in the AHDSS round to have perma-
nently left the surveillance area. The date of migration is
reported retrospectively by relatives and there may be
some misreporting. Thus, all those who reported to have
migrated just before their last clinic visit are here treated
as if they migrated on the day of their last clinic visit.
Re-engagement was defined as the resumption of clinic
visits in the same clinic or another clinic within the
AHDSS surveillance area. The latter is sometimes also
referred to as ‘silent transfers’ [12]. The identification of
silent transfers is facilitated through record linkage to the
Figure 1 Map of agincourt health and demographic surveillance system.
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AHDSS. National origin was based on the country of
father’s birth (i.e. South African or foreigner). Late pre-
sentation was a composite of CD4 counts of <250 cells/
lL and WHO stage III or IV at time of ART initiation.
Data analysis
In our first set of analyses, we used competing risks sur-
vival analysis to estimate the cumulative incidence of (i)
LTFU, (ii) all-cause mortality (as reported in clinic
records only) and (iii) documented transfers following
treatment initiation. The complement of these three prob-
abilities represents the proportion of patients who were
alive and still on ART in the same facility where they ini-
tiated treatment without interruptions in excess of
90 days following the last scheduled visit. For this analy-
sis, we only use data from the clinic visit logs. To impute
a return date, we added 30 days to all patients who never
returned after initiating ART (as their clinic return dates
were missing).
Our second set of analyses focuses on patients deemed
LTFU, and relies on data from both clinic visit logs and
the AHDSS. Again, we conduct competing risks survival
analysis to estimate the cumulative incidence of (i) re-
engagement, (ii) all-cause mortality and (iii) out-migra-
tion at or after LTFU. The complement of these three
probabilities represents the proportion of patients that
were LTFU but still alive, living in the study site and not
known to be on treatment at another facility.
Covariates of the outcomes of interest are assessed
using semi-parametric Cox regression models. Again, we
first model LTFU after treatment initiation. Patients’
exposure time is ended at the time that they become
LTFU, die or formally transfer out and right censored at
the date of the clinic data extraction (15 July 2017). A
similar approach is used for modelling the covariates of
patient outcomes following LTFU. As stipulated above,
we consider re-engagement with HIV care, out-migration
from the study area and death as competing risks.
Covariates with P-value below 0.05 in bivariate analyses
were included in the adjusted model. Schoenfeld residuals
were used to evaluate the proportional hazards assump-
tion (Figure S1–S4). Wherever the proportional hazards
assumption was violated, we included a linear interaction
between the covariate and analysis time. Data were anal-
ysed using Stata 14.0 (College Station, Texas, USA).
Results
Table 1 illustrates the characteristics of 3700 patients
who were linked to an AHDSS record and initiated ART
between 30 April 2014 and 15 July 2017. Majority of
the patients (88.8%; 3700/4168) who reported residency
in one of the AHDSS villages could be linked to an
AHDSS record. The attributes of linked and unlinked
records are further explored in a table in the supporting
information (Table S1). All of these patients were report-
edly ART na€ıve, but we cannot exclude that some previ-
ously received treatment elsewhere without declaring it as
such. At the time of ART initiation less than a quarter of
the patients were men and one-fifth of the patients were
pregnant or breastfeeding. The median age at ART initia-
tion was 38.7 years [Interquartile range (IQR): 31.9–
46.0 years] among men, 34.3 years [IQR: 27.1–
44.9 years] among non-pregnant women and 27.1 years
[IQR: 23.4–31.6 years] among pregnant or breastfeeding
women. Overall, 47.1% (1733/3681) of individuals pre-
sented late for care. The highest percentage of late pre-
sentation was observed among men (67%; 576/866),
followed by non-pregnant women (46%; 950/2077), and
pregnant or breastfeeding women (28%; 207/738). The
3700 patients jointly contributed a total of 6818 person-
years of observation time to the analyses. Of the 966
patients LTFU, 3.8% were lost within 1 year of ART ini-
tiation, 25.9% within 2 years and 81.9% within 3 years.
Patient status after ART initiation
Figure 2 and Table S2 show the probabilities of patients
being retained in care (n = 2704), dying (n = 28), LTFU
(n = 966) or transferring (n = 4). Using exclusively clinic
visit attendance records, the cumulative incidence of
LTFU, mortality and documented transfers at 1 year after
initiating ART were estimated at, 21.3% (95% CI 19.9–
22.8%), 0.67% (95% CI 0.43–1.02%) and 0.13% (95%
CI 0.04–0.86%), respectively. After 3 years, 41.0%
(95% CI 38.5–43.4%) were LTFU, 1.88% (95% CI
1.03–3.17%) had died and 0.13% (95% CI 0.04–0.86%)
were known to have transferred to another facility.
Patient status after LTFU
Figure 3 and Table S3 summarise the cumulative inci-
dence of re-engagement (n = 267), out-migration
(n = 298) and mortality (n = 44) after LTFU based on
the linked clinic-AHDSS database. The cumulative inci-
dence of re-engagement increased from 23.0% (95% CI
20.3–25.8%) at 1 year to 38.1% (95% CI 33.1–43.0%)
at year 3. The cumulative incidence of out-migration
increased from 22.8% (95% CI 20.1–25.5%) in year 1
to 49.4% (95% CI 43.1–55.3%) in year 3. About 15%
who out-migrated at time 0 are those who had migrated
between the date of last clinic visit and the date at which
they are considered LTFU. The cumulative incidence of
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mortality increased marginally from 4.5% (95% CI 3.3–
6.0%) at year 1 to 4.7% (95% CI 3.5–6.2%) at year 3.
The treatment status of the remaining 37% (357/966)
could not be ascertained using the linked clinic-AHDSS
dataset. After 3 years, about 10% of the patients were
LTFU. These are patients who interrupted care at the
place where they first initiated ART, are still living in the
study area, and are not known to re-engaged at the same
facility or transferred to another facility. The current
treatment and vital status of patients who migrated out
of the AHDSS area is also unknown.
Of the patients who resumed HIV care, 43.8% re-
engaged in the same health facility, 53.9% continued
treatment at another health facility and 2.2% continued
care at two facilities in the AHDSS area. The cumulative
incidence of transferring to another facility in the study
site was 3.2% (95% CI 2.2–4.4%) at 1 year and 14.4%
(95% CI 10.8–18.6%) at year 3.
Predictors of LTFU after ART initiation
Table 2 summarises the output of the regression model of
LTFU following ART initiation. In both crude and
Table 1 Characteristics of linked patients initiating ART
between April 2014 and July 2017 in the Agincourt sub-district
in Mpumalanga Province, South Africa
Patient characteristic n %
Sex & pregnancy status
Men 874 23.6
Women (non-pregnant) 2084 56.3
Women (pregnant or breastfeeding) 742 20.1
Missing 0
National origin
South African 2457 66.5
Foreigner 1240 33.5
Missing 3
Age at ART initiation (in years)
<20 220 6.0
20–29 1177 31.9
30–39 1160 31.4
40–49 631 17.0
≥50 507 13.7
Missing 5
Year of ART initiation
2014 634 17.1
2015 1223 33.0
2016 1282 34.7
2017 561 15.2
Missing 0
Late ART initiation
No 1948 52.9
Yes 1733 47.1
Missing 19
Number of patients contributing to
<1 year of exposure time to the analysis 629 17.0
1–2 years of exposure time to the analysis 1225 33.1
2–3 years of exposure time to the analysis 1285 34.7
>3 years of exposure time to the analysis 561 15.2
Missing 0
Number of patients LTFU since ART initiation
<1 years 37 3.8
1–2 years 213 22.0
2–3 years 541 56.0
>3 years 175 18.1
Missing 0
Total 3700 100
On ART
LTFU
Transferred
Dead
0
0.
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Figure 2 Patient outcomes following ART initiation using clinic
attendance records, Agincourt (2014–2017).
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Figure 3 Patient outcomes after LTFU ascertained through
record linkage between clinic records and AHDSS, Agincourt
(2014–2017).
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adjusted analysis, a linear interaction with time was
added to the model whenever the proportional hazards
assumption was violated. In many of these cases, the
interaction term suggests that initial differences between
patient subgroups decline as time goes on. Results of the
tests for the proportional hazards assumption are pre-
sented in Table S4 and Figure S1 in the supporting infor-
mation.
Pregnant or breastfeeding women had a more than
twofold increased risk of LTFU (adjusted hazard ratio
(AHR): 2.53; 95% CI 1.95–3.27) compared with non-
pregnant women, but their elevated risk of LTFU
attenuated by 39% every year. Men’s risk of LTFU was
initially not different from that of non-pregnant women,
but increased by 27% each calendar year. Former
Mozambican settlers had a 41% higher risk of LTFU
(AHR: 1.41; 95% CI 1.13–1.75) at time zero and it
declined by 33% every year.
LTFU risks for persons under 50 years of age were ini-
tially comparable, but disparities increased over time with
younger men and women experiencing higher LTFU risks
at longer durations. Men and women who initiated ART
in later calendar years (i.e. 2015, 2016 and 2017) were
at a higher risk of LTFU, but the interactions with time
all suggest that the differences decline as the time since
starting ART increases.
Predictors of re-engagement, mortality and out-migration
after LTFU
Table 3 summarises crude and adjusted hazard estimates
of re-engagement, mortality and out-migration following
LTFU from Cox regression models. The proportional
hazards assumption was violated in two instances, and
this was accommodated by the inclusion of a linear
interaction between the covariate of interest and analysis
time (Table S5 and Figures S2–S4). The interaction
between age and analysis time on mortality is only
included in the supporting information (Table S6) as it
led to very large coefficient estimates due to quasi-
separation in the data.
Initiating ART during pregnancy/breastfeeding (AHR:
0.61; 95% CI 0.44–0.84) or being a foreigner (AHR
0.68; 95% CI 0.51–0.89) were associated with a reduc-
tion in the risk of returning to care. Men and women
who initiated ART in later calendar years (i.e. 2015 and
2016) were at a lower risk of returning to care, and the
low risk intensified in the most recent period.
In univariate analysis, pregnant or breastfeeding
women had a 73% lower hazard (HR 0.27; 95% CI
0.09–0.79) of dying than non-pregnant women. After
adjustment of other covariates, the relationship was no
longer statistically significant. After adjustment, older age
(≥50 years) was associated with an increase in mortality
risk. The relative hazard of dying was higher among
patients who presented late for ART initiation (AHR
5.34; 95% CI 2.20–12.96) than in patients who pre-
sented early (WHO clinical stage I or II or with CD4
counts of >251 cells/lL).
In multivariate analysis, men (AHR: 0.65; 95% CI 0.48–
0.90) were at a lower risk of migrating out of AHDSS than
women. Patients who initiated ART in later years (i.e.
2015 and 2016) were also more likely to migrate out of the
study area than those who initiated in 2014.
Table 2 Factors associated with LTFU after ART initiation
LTFU
Crude HR
(95% CI)
Adjusted HR*
(95% CI)
Sex & pregnancy status
Women
(non-pregnant)
1 1
Pregnant or
breastfeeding women
2.64 (2.07–3.38) 2.53 (1.95–3.27)
Time-varying 0.69 (0.53–0.89) 0.61 (0.46–0.79)
Men 1.17 (0.89–1.52) 1.21 (0.92–1.58)
Time-varying 1.28 (1.01–1.63) 1.27 (1.00–1.63)
National origin
South African 1 1
Foreigner 1.39 (1.11–1.73) 1.41 (1.13–1.75)
Time-varying 0.74 (0.59–0.92) 0.67 (0.53–0.83)
Age at ART initiation
<20 years 2.16 (1.29–3.60) 1.61 (0.95–2.72)
Time-varying 2.02 (1.30–3.14) 2.44 (1.56–3.84)
20–29 years 2.63 (1.72–4.01) 1.89 (1.22–2.94)
Time-varying 0.92 (0.61–1.37) 1.20 (0.79–1.82)
30–39 years 2.04 (1.32–3.16) 1.70 (1.09–2.64)
Time-varying 0.77 (0.50–1.17) 0.86 (0.57–1.31)
40–49 years 1.92 (1.19–3.09) 1.76 (1.09–2.83)
Time-varying 0.84 (0.53–1.34) 0.88 (0.55–1.39)
≥50 years 1 1
Year of ART initiation
2014 1 1
2015 1.62 (1.17–2.23) 1.71 (1.24–2.36)
Time-varying 0.65 (0.49–0.86) 0.68 (0.51–0.90)
2016 3.17 (2.15–4.66) 3.41 (2.31–5.02)
Time-varying 0.19 (0.11–0.34) 0.21 (0.12–0.36)
2017 4.74 (1.58–14.27) 5.16 (1.71–15.53)
Time-varying 0.00 (0.00–0.02) 0.00 (0.00–0.02)
Late ART initiation
No 1
Yes 0.90 (0.80–1.03)
*LTFU:
No of subjects – 3692
No of failures – 964
Time at risk – 4621
Figures in bold showed statistical associations.
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Discussion
Using data from eight clinics in north-eastern South
Africa (Agincourt), we estimated that 21% and 41% of
the patients were LTFU at 12 and 36 months after
treatment initiation, respectively. The percentage of
deaths and transfers to other facilities within 3 years
that were recorded in the medical records were 2% and
0.1%, respectively. Our estimates of LTFU are higher
than those in studies from Johannesburg (14% at
12 months) [25] and Tanzania (18% at 12 months)
[26].
It is possible that LTFU rates have increased as a result
of ART programmes expanding to include all persons
newly diagnosed with HIV regardless of their CD4 cell
count or clinical stage, thereby including a larger number
of patients who initiate ART when they are still asymp-
tomatic [27]. This also offers an explanation for the
Table 3 Factors associated with re-engagement, mortality and out-migration following LTFU
Re-engagement Mortality Out-migration
Crude HR
(95% CI)
Adjusted HR*
(95% CI)
Crude HR
(95% CI)
Adjusted HR†
(95% CI)
Crude HR
(95% CI)
Adjusted
HR‡
(95% CI)
Sex & pregnancy status
Women
(non-pregnant)
1 1 1 1 1 1
Pregnant or
breastfeeding
women
0.58
(0.43–0.79)
0.61
(0.44–0.84)
0.27
(0.09–0.79)
0.69
(0.22–2.11)
1.03
(0.80–1.33)
1.02 (0.79–1.32)
Men 1.02
(0.77–1.35)
1.03
(0.77–1.39)
1.36
(0.73–2.53)
0.85
(0.45–1.60)
0.65
(0.47–0.89)
0.65 (0.48–0.90)
National origin
South African 1 1 1 1
Foreigner 0.69 (0.53–0.90) 0.68 (0.51–0.89) 1.32 (0.72–2.40) 1.11 (0.88–1.40)
Age at ART initiation
<20 years 0.49 (0.28–0.86) 0.58 (0.32–1.04) 0.08 (0.02–0.33) 0.12 (0.03–0.54) 1.64 (0.86–3.13)
20–29 0.64 (0.40–1.01) 0.77 (0.47–1.25) 0.05 (0.02–0.16) 0.08 (0.03–0.26) 1.79 (0.99–3.23)
30–39 0.69 (0.43–1.11) 0.77 (0.47–1.25) 0.26 (0.12–0.55) 0.28 (0.13–0.60) 1.57 (0.86–2.89)
40–49 0.85 (0.51–1.41) 0.84 (0.50–1.41) 0.33 (0.14–0.73) 0.33 (0.15–0.74) 1.24 (0.64–2.41)
≥50 years 1 1 1 1 1
Year of ART initiation
2014 1 1 1 1 1
2015 0.60 (0.37–0.96) 0.56 (0.34–0.90) 0.85 (0.44–1.65) 1.09 (0.82–1.46) 1.08 (0.81–1.44)
Time-varying 1.75 (0.98–3.14) 1.81 (1.01–3.26)
2016 0.22 (0.12–0.42) 0.20 (0.10–0.39) 0.48 (0.20–1.14) 1.51 (1.09–2.07) 1.48 (1.07–2.04)
Time-varying 7.41 (3.11–17.71) 8.47 (3.52–20.36)
Late ART initiation
No 1 1 1 1 1
Yes 1.28
(1.01–1.63)
1.02
(0.79–1.33)
7.86
(3.32–18.60)
5.37
(2.21–13.04)
0.91
(0.72–1.15)
*Re-engagement:
No of subjects – 960
No of failures – 265
Time at risk – 852
†Mortality:
No of subjects – 960
No of failures – 44
Time at risk – 852
‡Out-migration:
No of subjects – 966
No of failures – 298
Time at risk – 856
Figures in bold showed statistical associations.
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higher LFTU rates among patients who initiated treat-
ment in more recent calendar years.
Our finding that men and pregnant or breastfeeding
women were at an increased risk of LTFU corroborates the
results from other studies in sub-Saharan Africa [28–31].
For pregnant women in particular, it has been hypothesised
that they are more likely to disengage from care because
they are often asymptomatic and discontinue treatment
once the risk of onwards transmission to her child has dis-
sipated [32]. Women may also be more mobile to seek the
support of her relatives around or after childbirth and that
may also affect her health seeking behaviour.
Using linked clinic-HDSS data, we were in position to
evaluate the outcomes of patients after they disengaged
from ART services. Of the patients who were LTFU,
38% had re-engaged within 3 years, 49% migrated out
of the HDSS area and 5% had died. Consistent with two
systematic reviews of tracing studies [7, 33], death was
the least important cause of LTFU in this cohort. It is
also worth noting that mortality within 24 months of
LTFU is lower than that reported in tracing studies in the
Zambia where 8% had died within 2 years [34], and in
East Africa where 13% had died within 3 years [8].
There are two possible explanations for these differences.
On the one hand, these discrepancies with earlier tracing
studies could be explained by declining mortality among
patients LTFU over time. Even though our results do
indeed point in that direction, they did not reach statisti-
cal significance by conventional standards. They are,
however, plausible and could be attributed to a combina-
tion of factors including the availability of more effective
ART regimens that are more forgiving of lapses in treat-
ment and changes in ART initiation threshold guidelines,
which mean patients increasingly initiate ART when they
are still asymptomatic [22, 35, 36]. However, we cannot
exclude that the disparities with earlier tracing studies
are due to the fact that we could not establish the vital
status of patient who had migrated out of the HDSS area.
Even though migration is generally correlated with good
health [37], this could be a source of bias in our esti-
mates. Interestingly, men were less likely to have
migrated than women, but we have no data to explore
this association further.
We found that 14% of the patients had transferred to
another facility at 36 months. Similar levels of transfers
have been reported other African studies. In an individual
patient data meta-analysis of nine tracing studies con-
ducted in SSA, 15% of the patients had transferred to
another facility at the third year [38]. A previous study
cited the decentralisation of treatment and the proximity
to new health facility offering ART as the main reason
for transferring [11].
Study limitations
This study was done in one rural community in north-
east South Africa, thus it may not be possible to gener-
alise these findings. Second, ongoing studies such as the
Nkateko health service trial in this area may have
affected the study results. In brief, the main objective of
this trial was to enhance adherence to clinic visits using
phone-based reminders and home visits by lay health
workers among patients with hypertension [39]. Of note,
some of the hypertensive patients were also HIV-infected
and thus benefited by being continually reminded of their
clinic visits. Third, clinical data that was used in this
study was obtained from patient attendance records and
this restricted the variables that were available for analy-
sis. Fourth, some patients may have been enrolled in dif-
ferentiated care models that did not require them to visit
clinics with the same frequency. Failing to account for
these patients distinct visit patterns may have resulted to
an overestimation of LTFU in this study. However, the
rollout of differentiated care only started in late 2016,
thus the number of patients enrolled in differentiated care
model may have been negligible. Last, we did not quan-
tify the quality of data linkage. A study in Tanzania that
used a similar data linkage approach, managed to link
84% of the patients who declared residency in the HDSS
area to an HDSS record [23].
Conclusion
As observed in clinical cohort studies in other African pop-
ulations, LTFU among patients starting ART in north-east-
ern South Africa is relatively high. LTFU rates are typically
higher among pregnant women but are also increasing in
other patient subgroups as treatment eligibility criteria
have expanded and patients increasingly start ART shortly
after diagnosis when they are still asymptomatic. Whereas
this tendency is of concern in light of the prevention of
onwards transmission, we also found that re-engagement
in care is common (40% within 3 years) and mortality rel-
atively low (5% within 3 years). The LTFU and patient
mobility rates identified in this population further suggest
that surveillance methods that solely rely on clinic records
without unique patient identifiers will be severely limited
to accurately represent treatment coverage.
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